Table 1 Percentage of viability for each treatment at all concentrations and moments
From: Short exposure to tranexamic acid does not affect, in vitro, the viability of human chondrocytes
20 mg/ml | 50 mg/ml | 70 mg/ml | 100 mg/ml | |
|---|---|---|---|---|
10′/0 h | ||||
Untreated % viability | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 |
WFI % viability | 77.75 ± 20.42 | 74.10 ± 25.56 | 55.45 ± 25.03 | − 11.95 ± 10.92 |
W-TXA % viability | 91.77 ± 16.76 | 82.56 ± 12.92 | 72.21 ± 22.90 | 20.04 ± 24.36 |
M-TXA % viability | 92.58 ± 21.31 | 85.34 ± 23.30 | 80.66 ± 17.37 | 80.62 ± 19.54 |
10′/24 h | ||||
Untreated % viability | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 |
WFI % viability | 77.46 ± 35.21 | 70.12 ± 36.97 | 57.67 ± 38.81 | − 4.14 ± 10.54 |
W-TXA % viability | 106.48 ± 46.19 | 95.36 ± 37.60 | 81.53 ± 33.80 | 22.88 ± 16.75 |
M-TXA % viability | 92.45 ± 25.20 | 86.79 ± 16.73 | 89.49 ± 15.91 | 94.38 ± 15.99 |
10′/48 h | ||||
Untreated % viability | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 |
WFI % viability | 78.78 ± 28.05 | 74.40 ± 26.51 | 59.43 ± 28.64 | − 6.32 ± 6.79 |
W-TXA % viability | 94.02 ± 30.07 | 87.85 ± 30.19 | 74.73 ± 28.23 | 32.51 ± 23.24 |
M-TXA % viability | 94.45 ± 34.62 | 88.82 ± 25.44 | 93.74 ± 21.35 | 84.15 ± 13.19 |
24 h | ||||
Untreated % viability | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 |
WFI % viability | 116.66 ± 24.37 | 92.40 ± 26.77 | 50.93 ± 20.52 | 11.06 ± 6.23 |
W-TXA % viability | 99.33 ± 24.38 | 60.97 ± 12.99 | 48.93 ± 14.46 | 5.99 ± 12.91 |
M-TXA % viability | 93.13 ± 14.37 | 63.38 ± 15.14 | 47.25 ± 21.51 | 24.34 ± 29.53 |
48 h | ||||
Untreated % viability | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 | 100 ± 0.00 |
WFI % viability | 121.51 ± 37.41 | 87.10 ± 40.25 | 38.76 ± 20.37 | 9.95 ± 7.51 |
W-TXA % viability | 85.22 ± 25.67 | 41.16 ± 25.81 | 29.35 ± 30.97 | 2.38 ± 11.48 |
M-TXA % viability | 75.83 ± 17.39 | 38.07 ± 20.36 | 29.29 ± 29.23 | 17.41 ± 33.14 |